Eculizumab

American Journal of Health-System Pharmacy

Volumn 65, Issue 17, 2008, Pages 1609-1615

  Davis, Jennifer ^a   Bonk, Mary Ellen ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University HealthSystem Consortium   (United States)

Author keywords

Antibodies; Dosage; Drug administration; Drug interactions; Eculizumab; Hemoglobinuria; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

COMPLEMENT COMPONENT C5; ECULIZUMAB;

BACKACHE; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYTOLYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEMOLYSIS; HERPES SIMPLEX; HUMAN; MENINGOCOCCOSIS; MYALGIA; NAUSEA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SINUSITIS;

EID: 51649114242     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080043     Document Type: Review

References (20)

1. Hillmen P, Lewis SM, Bessler M et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995; 333:1253-8.
2. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007; 137:181-92.
3. Parker C, Omine M, Richards S et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005; 106:3699-709.
4. Soliris (eculizumab) concentrated solution for intravenous infusion package insert. Cheshire, CT: Alexion Pharmaceuticals, Inc.; 2007.
5. Rosse WF, Hillmen P, Schreiber AD. Immune-mediated hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2004:48-62.
6. Matis LA, Rollins SA. Complement-specific antibodies: designing novel anti-inflammatories. Nat Med. 1995; 1:839-42.
7. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355:1233-43.
8. Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004; 350:552-9.
9. Hill A, Hillmen P, Richards SJ et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005; 106:2559-65.
10. FDA grants priority review for Soliris (eculizumab) BLA for treatment of paroxysmal nocturnal hemoglobinuria news release. Cheshire, CT: Alexion Pharmaceuticals, Inc.; 2006 Nov 14.
11. Alexion Pharmaceuticals submits Biologics License Application for Soliris (eculizumab): European application on track for submission in 2006 news release. Cheshire, CT: Alexion Pharmaceuticals, Inc.; 2006 Sep 20.
12. ClinicalTrials.gov resource page, http://clinicaltrials.gov (accessed 2007 Jul 31).
13. European Medicines Agency. EPARs for authorised products for human use: Soliris. European public assessment report. www.emea.europa.eu/humandocs/PDFs/ EPAR/soliris/H-791-en6.pdf (accessed 2007 Jul 25).
14. Richards SJ, Cullen MJ, Dickinson AJ et al. Long term stability of red cell responses in patients with paroxysmal nocturnal haemoglobinuria (PNH) on eculizumab therapy: implications for the future treatment and management of PNH. Br J Haematol. 2006; 133(suppl 1):16. Abstract 169.
15. Young NS, Antonioli E, Rotoli B et al. Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: interim Shepherd phase III clinical study. Blood. 2006: 108. Abstract 971.
16. Hillmen P, Muus P, Duhrsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. http://bloodjournal. hematologylibrary.org/cgi/ content/ abstract/blood-2007-06-095646v1 (accessed 2007 Oct 12).
17. Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica. 2005; 90(suppl 12):3-5. Letter.
18. Red Book. Montvale, NJ: Thomson PDR; 2008.
19. For patients: the Soliris OneSource program. www.soliris.net/ for_patients.html (accessed 2007 Nov 13).
20. Hill A, Ridley SH, Esser D et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood. 2006; 107:2131-7.